Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting – QNT Press Release

Interim results show sustained reduction in hereditary angioedema attacks and no new safety signals in patients treated for one year

CARLSBAD, Calif., Nov. 13, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today presented positive results from a Phase 2 open-label extension (OLE) study evaluating the safety and efficacy of its investigational antisense medicine, donidalorsen, in patients with hereditary angioedema (HAE), a rare and devastating inflammatory disease. Interim data after all patients completed 1 year of treatment in the study showed a sustained reduction in HAE attacks and no new safety signals following treatment with donidalorsen. Treatment with donidalorsen resulted in an overall sustained mean reduction in HAE attack rates of 95% from baseline. For patients treated with donidalorsen, 99.6% of study days were HAE attack-free.

The data were presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Louisville, Ky. Additional details can be found on the ACAAI website.

“Today’s data further enhance donidalorsen’s profile and potential to provide significant sustained protection from attacks for people living with hereditary angioedema,” said Richard S. GearyPh.D., executive vice president and chief development officer at Ionis. “The positive results of the Phase 2 OLE are encouraging as we continue evaluating donidalorsen, a potential …

Full story available on

Source link

Recommended For You

About the Author: News Center